Trials / Not Yet Recruiting
Not Yet RecruitingNCT07265895
Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations
Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations, Monocentric Retrospective Observational Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- IRCCS San Raffaele · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Inherited Retinal Diseases (IRDs) are a heterogeneous group of genetically based degenerative retinal disorders, representing a major cause of visual impairment and blindness in working-age adults. Despite the approval of the first gene therapy for RPE65-related IRD (voretigene neparvovec) in 2017, most IRDs remain untreatable, though many gene therapies are in development. Effective trial design and therapy development require a deep understanding of disease natural history and genotype-phenotype correlations. Over 270 IRD-associated genes are known (e.g., ABCA4, USH2A, RPGR, PRPH2, BEST1), each linked to distinct phenotypes and clinical progression. This retrospective study analyzes clinical, functional, and imaging data (Optical Coherence Tomography, Fundus Autofluorescence, Microperimetry) from a large, genetically characterized IRD cohort at the IRCCS Ospedale San Raffaele up to December 31, 2025. The aims are to describe natural history, define genotype-phenotype relationships, and identify structural and functional outcome measures useful for future clinical trial endpoints, supporting personalized prognosis and trial design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention: Observational Cohort | no intervention, natural history study |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2025-12-05
- Last updated
- 2025-12-05
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT07265895. Inclusion in this directory is not an endorsement.